Open Access

Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients

  • Authors:
    • Sayaka Obayashi
    • Jun Horiguchi
    • Toru Higuchi
    • Ayaka Katayama
    • Tadashi Handa
    • Bolag Altan
    • Tuya Bai
    • Pinjie Bao
    • Halin Bao
    • Takehiko Yokobori
    • Masahiko Nishiyama
    • Tetsunari Oyama
    • Hiroyuki Kuwano
  • View Affiliations

  • Published online on: July 27, 2017     https://doi.org/10.3892/ijo.2017.4085
  • Pages: 781-790
  • Copyright: © Obayashi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Stathmin1 (STMN1) regulates progression in various cancers. The present study aimed to determine the relationship between STMN1 expression and several cancer-related markers in breast cancer. Using immunohistochemistry, we evaluated STMN1, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67, epidermal growth factor receptor (EGFR), CK5/6, CD44, CD24, aldehyde dehydrogenase 1, E-cadherin, epithelial cell adhesion molecule, and vimentin in 237 breast cancer patients and the clinical significance of STMN1. STMN1 expression was evaluated in 51 breast cancer cell lines, and the prognostic value of STMN1 was calculated. Higher STMN1 expression was detected in cancer tissues and was predominantly localized in the cytoplasm. High STMN1 expression was associated with the triple negative subtype, nuclear grade progression, high expression of Ki-67, EGFR, CK5/6, E-cadherin and high CD44/low CD24. According to gene expression-based outcome for breast cancer online and the Kaplan-Meier plotter, STMN1 expression was higher in basal-type cell lines than in luminal-type cell lines, and overall survival and post-progression survival in the high STMN1 expression breast cancer patients were shorter than in low STMN1 expression patients. High STMN1 expression is a possible marker of breast cancer aggressiveness in association with proliferation, phenotype and cancer stem cell type.
View Figures
View References

Related Articles

Journal Cover

September 2017
Volume 51 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Obayashi, S., Horiguchi, J., Higuchi, T., Katayama, A., Handa, T., Altan, B. ... Kuwano, H. (2017). Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients. International Journal of Oncology, 51, 781-790. https://doi.org/10.3892/ijo.2017.4085
MLA
Obayashi, S., Horiguchi, J., Higuchi, T., Katayama, A., Handa, T., Altan, B., Bai, T., Bao, P., Bao, H., Yokobori, T., Nishiyama, M., Oyama, T., Kuwano, H."Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients". International Journal of Oncology 51.3 (2017): 781-790.
Chicago
Obayashi, S., Horiguchi, J., Higuchi, T., Katayama, A., Handa, T., Altan, B., Bai, T., Bao, P., Bao, H., Yokobori, T., Nishiyama, M., Oyama, T., Kuwano, H."Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients". International Journal of Oncology 51, no. 3 (2017): 781-790. https://doi.org/10.3892/ijo.2017.4085